1668-01-5Relevant articles and documents
Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice
Vincent, Jessica,Adura, Carolina,Gao, Pu,Luz, Antonio,Lama, Lodoe,Asano, Yasutomi,Okamoto, Rei,Imaeda, Toshihiro,Aida, Jumpei,Rothamel, Katherine,Gogakos, Tasos,Steinberg, Joshua,Reasoner, Seth,Aso, Kazuyoshi,Tuschl, Thomas,Patel, Dinshaw J.,Glickman, J. Fraser,Ascano, Manuel
, (2017/10/09)
Cyclic GMP-AMP synthase is essential for innate immunity against infection and cellular damage, serving as a sensor of DNA from pathogens or mislocalized self-DNA. Upon binding double-stranded DNA, cyclic GMP-AMP synthase synthesizes a cyclic dinucleotide that initiates an inflammatory cellular response. Mouse studies that recapitulate causative mutations in the autoimmune disease Aicardi-Goutières syndrome demonstrate that ablating the cyclic GMP-AMP synthase gene abolishes the deleterious phenotype. Here, we report the discovery of a class of cyclic GMP-AMP synthase inhibitors identified by a high-throughput screen. These compounds possess defined structure-activity relationships and we present crystal structures of cyclic GMP-AMP synthase, double-stranded DNA, and inhibitors within the enzymatic active site. We find that a chemically improved member, RU.521, is active and selective in cellular assays of cyclic GMP-AMP synthase-mediated signaling and reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome. RU.521 will be useful toward understanding the biological roles of cyclic GMP-AMP synthase and can serve as a molecular scaffold for development of future autoimmune therapies.
NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS
-
Page/Page column 70, (2015/12/08)
A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
-
, (2008/06/13)
The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as modulators of SKCa, IKCa and BKCa channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.